atezolizumab alone (n=406) vs. no additional treatment (n=403)
randomized controlled trial
atezolizumab
1200 mgintravenous atezolizumab fora total of 16 cycles or 1 year, Dose reductions ofatezolizumab were not permitted.
observation
Crossover was not permitted
MIBC - NA - all population
selction regardless of PDL1 status
opan-label
192 hospitals, academic centres, and community oncology practices across 24 countries or regions
P3/ two sided with two interim analysis (OS). If results from the disease-freesurvival analysis were significant at an α value of 0·05,the analysis of overall survival was to be performed at anα level of 0·05,
IMvigor010 study evaluating Tecentriq ® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC)